Isoallolithocholic acid ameliorates intestinal inflammation via metabolically reprogrammed macrophages
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-29 03:52
摘要：
IsoalloLCA, a bile acid metabolite, has been shown to alleviate intestinal inflammation in pediatric patients with inflammatory bowel disease (IBD). The study demonstrates that isoalloLCA reduces TNF production and enhances the expression of anti-inflammatory regulatory T cells in both human and murine models. By metabolically reprogramming macrophages, isoalloLCA enhances oxidative phosphorylation, thereby amplifying its anti-inflammatory effects. This research highlights the potential of isoalloLCA as a promising therapeutic avenue for treating IBD, addressing a significant global health concern.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.0分
technical_barrier_competition
0.5分
关键证据
IsoalloLCA treatment decreases TNF production in pediatric IBD patients.
IsoalloLCA alleviates acute intestinal inflammation in murine models.
The study shows isoalloLCA enhances the expression of regulatory T cell transcription factor Foxp3.
真实性检查
否
AI评分总结
IsoalloLCA, a bile acid metabolite, has been shown to alleviate intestinal inflammation in pediatric patients with inflammatory bowel disease (IBD). The study demonstrates that isoalloLCA reduces TNF production and enhances the expression of anti-inflammatory regulatory T cells in both human and murine models. By metabolically reprogramming macrophages, isoalloLCA enhances oxidative phosphorylation, thereby amplifying its anti-inflammatory effects. This research highlights the potential of isoalloLCA as a promising therapeutic avenue for treating IBD, addressing a significant global health concern.